VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Pseudorabies Subunit gB Protein Vaccine
Vaccine Information
  • Vaccine Name: Pseudorabies Subunit gB Protein Vaccine
  • Target Pathogen: Pseudorabies virus
  • Target Disease: Aujeszky's disease
  • Vaccine Ontology ID: VO_0004041
  • Type: Recombinant vector vaccine
  • Status: Research
  • gB gene engineering:
    • Type: Recombinant vector construction
    • Description:
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Host Strain: C57BL/6
  • Vaccination Protocol: Groups of female mice were immunized with replication-incompetent adenoviruses expressing PrV glycoprotein (rAd-gB) by either the intranasal (i.n.) or intramuscular (i.m.) route. For i.m. administration, recombinant adenoviruses (106 pfu/mouse) were injected into the anterior tibialis muscle three times at weekly intervals (0, 7, and 14 days). The i.n. immunizations were also performed three times at weekly intervals (0, 7, and 14 days) by depositing 106 pfu of recombinant adenovirus onto the nares of deeply anesthetized mice. Control mice were immunized with replication-incompetent adenovirus expressing the LacZ gene (rAd-LacZ) (Han et al., 2008).
  • Challenge Protocol: The immunized mice were infected i.n. with the virulent PrV YS strain (10 LD50) two weeks after the final immunization. The challenged mice were examined daily to quantify the number of dead animals. Mice generally began to exhibit clinical signs of illness 3 to 4 days post-challenge (Han et al., 2008).
  • Efficacy: Recombinant adenovirus expressing gB (rAd-gB) was found to induce effective protective immunity against a virulent viral infection, regardless of whether it was administered via the muscular or systemic route (Han et al., 2008).
  • Host Ifng (Interferon gamma) response
    • Description: In splenocytes and popliteal lymph node cells, IFN-gamma was induced to a significantly higher level in immunized animals as compared to replication-incompetent adenovirus expressing LacZ (rAd-LacZ) vaccinated mice. These elevated levels were detected 2 weeks after the final immunization
    • Detailed Gene Information: Click Here.
  • Host Il2 response
    • Description: In splenocytes and popliteal lymph node cells, IL-2 was induced to a significantly higher level in immunized animals as compared to replication-incompetent adenovirus expressing LacZ (rAd-LacZ) vaccinated mice. These elevated levels were detected 2 weeks after the final immunization (Han et al., 2008).
    • Detailed Gene Information: Click Here.
  • Host Il4 (interleukin 4) response
    • Description: In splenocytes and popliteal lymph node cells, IL-4 was induced to a significantly higher level in immunized animals as compared to replication-incompetent adenovirus expressing LacZ (rAd-LacZ) vaccinated mice. These elevated levels were detected 2 weeks after the final immunization (Han et al., 2008).
    • Detailed Gene Information: Click Here.
References
Han et al., 2008: Han YW, Aleyas AG, George JA, Kim SJ, Kim HK, Yoon HA, Yoo DJ, Kang SH, Kim K, Eo SK. Polarization of protective immunity induced by replication-incompetent adenovirus expressing glycoproteins of pseudorabies virus. Experimental & molecular medicine. 2008; 40(6); 583-595. [PubMed: 19116444].